Please login to the form below

Not currently logged in
Email:
Password:

XLH

This page shows the latest XLH news and features for those working in and with pharma, biotech and healthcare.

NICE U-turn on Crystiva for rare bone disease

NICE U-turn on Crystiva for rare bone disease

This marks a step change in treatment for XLH, emphasised through the emotional testimonies provided by patient groups and clinicians following the first evaluation consultation.”. ... Characterised by bowed or bent legs, a short stature, bone pain and

Latest news

  • NICE set to reject Kyowa Kirin’s Crysvita for XLH NICE set to reject Kyowa Kirin’s Crysvita for XLH

    The twice-monthly injection was given a conditional approval by the European Medicines Agency (EMA) earlier this year to treat children and young people with X-linked hypophosphataemia (XLH), a genetic ... XLH only affects around 250 children and young

  • Rigel and Ultragenyx claim approvals for rare drugs Rigel and Ultragenyx claim approvals for rare drugs

    Tavalisse and Crysvita are set to treat patients with chronic ITP and XLH, respectively. ... Ultragenyx’s FDA approval was for Crysvita (burosumab), which has become the first approved drug for adults and children ages one year and older with X-linked

More from news
Approximately 2 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
W2O Group

W2O Group is an integrated marketing agency with expertise in brand and digital strategy, creative development and communications services. We...

Latest intelligence

AstraZeneca’s oncology renaissance
Susan Galbraith played a key role in restoring AstraZeneca’s place in cancer drug development – she talks about the future of oncology and why there’s more to be done to...
Navigating the antibiotic resistance crisis
Blue Latitude Health speaks to Tara DeBoer, PhD, Postdoctoral Researcher and CEO of BioAmp Diagnostics to explore the antimicrobial resistance crisis, and learn how a simple tool could support physicians...
Combined immunotherapies – potential and pitfalls
‘Combining therapeutic compounds is the first logical step towards better results, namely higher rates of patients responding to treatment, with deeper and more sustained responses’...

Infographics